Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $1.46 in the prior trading day, Nektar Therapeutics (NASDAQ: NKTR) closed at $1.65, up 13.01%. In other words, the price has increased by $13.01 from its previous closing price. On the day, 1.71 million shares were traded. NKTR stock price reached its highest trading level at $1.65 during the session, while it also had its lowest trading level at $1.445.
Ratios:
Our goal is to gain a better understanding of NKTR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.14 and its Current Ratio is at 6.45. In the meantime, Its Debt-to-Equity ratio is 1.76 whereas as Long-Term Debt/Eq ratio is at 1.61.
Jefferies Upgraded its Underperform to Hold on May 10, 2023, whereas the target price for the stock was revised from $1.50 to $1.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 20 ’24 when ROBIN HOWARD W sold 20,033 shares for $0.68 per share. The transaction valued at 13,622 led to the insider holds 879,889 shares of the business.
Zalevsky Jonathan sold 9,014 shares of NKTR for $6,130 on Feb 20 ’24. The Chief R&D Officer now owns 265,025 shares after completing the transaction at $0.68 per share. On Feb 20 ’24, another insider, Wilson Mark Andrew, who serves as the Chief Legal Officer of the company, sold 7,606 shares for $0.68 each. As a result, the insider received 5,172 and left with 236,674 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 302969696 and an Enterprise Value of 229754400. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.36 while its Price-to-Book (P/B) ratio in mrq is 2.41. Its current Enterprise Value per Revenue stands at 2.549 whereas that against EBITDA is -1.803.
Stock Price History:
The Beta on a monthly basis for NKTR is 0.71, which has changed by 1.0886075 over the last 52 weeks, in comparison to a change of 0.23568535 over the same period for the S&P500. Over the past 52 weeks, NKTR has reached a high of $1.75, while it has fallen to a 52-week low of $0.41. The 50-Day Moving Average of the stock is 57.03%, while the 200-Day Moving Average is calculated to be 137.34%.
Shares Statistics:
The stock has traded on average 2.53M shares per day over the past 3-months and 1807020 shares per day over the last 10 days, according to various share statistics. A total of 191.38M shares are outstanding, with a floating share count of 177.94M. Insiders hold about 3.09% of the company’s shares, while institutions hold 64.78% stake in the company. Shares short for NKTR as of 1713139200 were 3113324 with a Short Ratio of 1.23, compared to 1710460800 on 2514998. Therefore, it implies a Short% of Shares Outstanding of 3113324 and a Short% of Float of 3.63.
Earnings Estimates
Nektar Therapeutics (NKTR) is presently subject to a detailed evaluation by 3.0 analysts, each offering their unique perspectives on its market standing.On average, analysts expect EPS of -$0.19 for the current quarter, with a high estimate of -$0.17 and a low estimate of -$0.22, while EPS last year was -$0.73. The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.15 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.65 and -$1.21 for the fiscal current year, implying an average EPS of -$0.88. EPS for the following year is -$0.71, with 4.0 analysts recommending between -$0.31 and -$1.0.
Revenue Estimates
For the next quarter, 3 analysts are estimating revenue of $15.34M. There is a high estimate of $20.62M for the next quarter, whereas the lowest estimate is $5.4M.
A total of 4 analysts have provided revenue estimates for NKTR’s current fiscal year. The highest revenue estimate was $85.33M, while the lowest revenue estimate was $22.2M, resulting in an average revenue estimate of $67.51M. In the same quarter a year ago, actual revenue was $90.12MBased on 4 analysts’ estimates, the company’s revenue will be $62.27M in the next fiscal year. The high estimate is $81.92M and the low estimate is $22.9M.
